title: Dalfampridine extended release tablets: 1 year of postmarketing safety experience in the US.
abstract: BACKGROUND
  Dalfampridine extended release tablets (dalfampridine-ER; prolonged-, modified, or sustained-release fampridine in some countries) were approved in the US to improve walking in patients with multiple sclerosis, as demonstrated by improvement in walking speed. Postmarketing safety experience is available from exposure of approximately 46,000 patients in the US from product approval through March 2011.
  
  
  OBJECTIVE
  To provide a descriptive analysis of all spontaneously reported postmarketing adverse events (AEs) for dalfampridine-ER since product launch.
  
  
  METHODS
  AE data were extracted from the safety database from product launch through March 31, 2011; AEs were classified using the Medical Dictionary for Regulatory Activities. Seizure cases were reviewed for patient demographics, time to event from treatment onset, and presence of additional risk factors.
  
  
  RESULTS
  THE MOST FREQUENTLY REPORTED POSTMARKETING AES WERE SIMILAR TO THOSE REPORTED DURING CLINICAL DEVELOPMENT: dizziness, insomnia, balance disorder, headache, nausea, urinary tract infection, asthenia, and back pain (all included in US product labeling). New clinically significant findings are related to lack of efficacy and inappropriate dosing. Of the approximately 46,000 patients exposed, 85 seizures were reported (∼5.4/1000 patient-years), of which 82 were reported or confirmed by a health care practitioner (∼5.2/1000 patient-years). Beyond the intrinsic multiple sclerosis-related seizure risk, more than half of the 85 cases (62%) had an additional potential risk factor for seizure including a previous history of convulsions, renal impairment, incorrect dosing, or use of concurrent medications with a labeled seizure risk. Duration of treatment prior to the seizure ranged from one dose to 365 days; 26/85 (31%) patients suffered a seizure within a week of starting treatment.
  
  
  CONCLUSIONS
  Spontaneous safety data from the US postmarketing experience were consistent with the safety profile seen during clinical development. Although first-year seizure incidence was not substantially different from that observed in dalfampridine-ER clinical trials, patients should be monitored for concomitant use of drugs that lower seizure threshold.
authors: Acorda Therapeutics, Inc, Ardsley, NY, USA;
authors: Michele
authors: M
authors: Jara
authors: Graham
authors: G
authors: Barker
authors: Herbert R
authors: HR
authors: Henney
keywords: adverse events; dalfampridine; fampridine; multiple sclerosis; postmarketing safety; seizure
references: Epilepsia. 2003 Nov;44(11):1445-8
references: 14636354
references: J Neurol Neurosurg Psychiatry. 2005 Apr;76(4):469-75
references: 15774430
references: Expert Opin Drug Saf. 2012 Jul;11(4):651-7
references: 22703551
references: Lancet. 2009 Feb 28;373(9665):732-8
references: 19249634
references: Epilepsy Behav. 2003 Feb;4(1):6-12
references: 12609222
references: Curr Med Res Opin. 2011 Jul;27(7):1415-23
references: 21595605
references: Clin Neuropharmacol. 1993 Jun;16(3):195-204
references: 8504436
references: CNS Drugs. 2009 Oct;23(10):805-15
references: 19739692
references: Neurology. 1994 Jun;44(6):1054-9
references: 8208399
references: Mult Scler. 2002 Dec;8(6):495-9
references: 12474990
references: Epilepsia. 2008 Jun;49(6):948-53
references: 18336559
references: Ann Neurol. 2010 Oct;68(4):494-502
references: 20976768
references: Clin Ther. 2012 May;34(5):1056-69
references: 22497693
references: Neurology. 2008 Oct 7;71(15):1134-41
references: 18672472